GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ETON · Mar 31, 2024

Eton Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001437749-24-015697General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.18% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-31.04% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

29.10% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

62.85% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-10.04% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8.17% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

10.31% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.00%
Current: 0.18%
Delta: 0.18%

Cash Generation Decreased

Previous: 21.54%
Current: -31.04%
Delta: -52.58%

Inventory Pressure Increased

Previous: 2.88%
Current: 29.10%
Delta: 26.22%

Margin Decreased

Previous: 66.56%
Current: 62.85%
Delta: -3.71%

Profitability Decreased

Previous: -3.77%
Current: -10.04%
Delta: -6.28%

R And D Intensity Decreased

Previous: 10.50%
Current: 8.17%
Delta: -2.33%

Sbc Intensity Increased

Previous: 9.91%
Current: 10.31%
Delta: 0.39%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ETON Fundamental State →Has State · Eton Pharmaceuticals, Inc. →Transitioned To · ETON Fundamental State →Transitioned To · ETON CAPEX_INTENSITY_INCREASED →Transitioned To · ETON CASH_GENERATION_DECREASED →Transitioned To · ETON INVENTORY_PRESSURE_INCREASED →Transitioned To · ETON MARGIN_DECREASED →Transitioned To · ETON PROFITABILITY_DECREASED →Transitioned To · ETON R_AND_D_INTENSITY_DECREASED →Transitioned To · ETON SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.